Abstract:Title:Combination of Tigecycline and HomoharringtonineSynergistically Enhances anti-Leukemia and anti-MDS Effect Followed by Inhibiting Mitochondrial Translation through AKT/mTORPathway and Downregulation of anti-Apoptotic Proteins. Abstract Antimicrobial tigecycline was identified toxic to leukemia stem and progenitor cells compared to their normal counterparts and also showed antileukemic activity in mouse models of human leukemia through inhibiting mitochondrial translation. We aimed to investigate the effect of several antineoplastic drugs (Idarubicin, Homoharringtonine, Chidamide)in combination with tigecycline on the proliferation of myeloid leukemia cells and MDS cells, to select the most efficient combination group and explore the associated mechanisms of these combination therapies. Cell proliferation was tested by MTT assay and CFU-GM assay. Cell apoptosis was evaluated by Annexin V and PI staining in cell culture, TUNEL assay and transmission electron microscopy in animal study.The tumor volume in mouse model was measured with a vernier caliper. Molecular studies were conducted using microarray expression analysis, which was used to explore associated pathways. Real-time quantitative reverse transcription-PCR, western blot and immunohistochemistry were used to assess regulation of AKT/mTORpathway. Among three antineoplastic drugs agents in combining with tigecycline, the combination of tigecycline and homoharringtonineinduced synergistic cell death in SKM-1 cells, and this effect was verified in MDS-L, molml13 cells and primary cells isolated from patients diagnosed with MDS. Importantly, tumor growth inhibition in this combination was found to be higher than in single agent or controls in vivo. Moreover, combination of the two agents induced apoptosis and depression of the AKT/mTORpathway in both MDS and AML cell culture and animal studies. The findings demonstrated that combination of tigecycline and homoharringtoninehad synergistic anti-MDS and anti-AML effects. AKT phosphorylation down-regulates phosphorylation of PRAS40, further downregulating protein levels of p-raptor and mTORC1.Down-regulation of AKT phosphorylation down-regulates the mTOR phosphorylation, followed by phosphorylation of 4E-BP1.The unactivated 4E-BP1 binds to eIF4E, enhancing the inhibition of translation.Down-regulation of p-rictor and down-regulation of mTORC2 resulted in down-regulation of phosphorylation of AKT ser473.Down-regulation of AKT phosphorylation down-regulates NF-kB phosphorylation, followed by BCL-2 expression.Tune to promote cell death.Mitochondrial translation was inhibited.The subunit Cox-1 expression of the respiratory complex IV in the electron transport chain encoded by the gene in the mitochondria is down-regulated. The nuclear gene-encoded subunit Cox-4 expression was not affected. These effects were mainly attributed to the inhibition of mitochondrial translation of AKT/mTORpathway inhibitors and downregulation of anti-apoptotic proteins. Keywords: Tigecycline, Homoharringtonine, AKT,mTOR,Myelodysplastic syndromes, Acute myeloid leukemia Disclosures No relevant conflicts of interest to declare.

LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells.

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed by Inhibiting Mitochondrial Translation Through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.

Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells

A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer

Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis

Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles

Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Pegylated Phosphotidylethanolamine Inhibiting P-Glycoprotein Expression and Enhancing Retention of Doxorubicin in MCF7/ADR Cells

Dual-Drug Backboned Polyprodrug with a Predefined Drug Combination for Synergistic Chemotherapy

Preclinical Development Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP 9 X and Mcl-1

Synergistic Disruption of Metabolic Homeostasis through Hyperbranched Poly(ethylene glycol) Conjugates as Nanotherapeutics to Constrain Cancer Growth

Coadministration of Glycolipid-Like Micelles Loading Cytotoxic Drug with Different Action Site for Efficient Cancer Chemotherapy

The combination therapy of doxorubicin and quercetin on multidrug resistant breast cancer and their sequential delivery by reduction-sensitive hyaluronic acid-based conjugate / D-α-tocopheryl polyethylene glycol 1000 succinate mixed micelles.

Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity

YHHU0895, a Novel Synthetic Small-Molecule Microtubule-Destabilizing Agent, Effectively Overcomes P-glycoprotein-mediated Tumor Multidrug Resistance.

Antiproliferative effects of LY-2183240 combined with various chemotherapeutic drugs in an isobolographic in vitro model of malignant melanoma

PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer